THES2
MCID: TRC078
MIFTS: 35

Trichohepatoenteric Syndrome 2 (THES2)

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Liver diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Trichohepatoenteric Syndrome 2

MalaCards integrated aliases for Trichohepatoenteric Syndrome 2:

Name: Trichohepatoenteric Syndrome 2 58 76 30 13 6 74
Thes2 58 76
Syndrome, Trichohepatoenteric, Type 2 41

Characteristics:

OMIM:

58
Inheritance:
autosomal recessive

Miscellaneous:
onset in the first few months of life patients may need lifelong total parenteral nutrition


HPO:

33
trichohepatoenteric syndrome 2:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Trichohepatoenteric Syndrome 2

OMIM : 58 Trichohepatoenteric syndrome (THES) is a rare and severe disease characterized by intrauterine growth retardation, facial dysmorphism, hair abnormalities, intractable diarrhea, and immunodeficiency (summary by Fabre et al., 2012). For a discussion of genetic heterogeneity of trichohepatoenteric syndrome, see THES1 (222470). (614602)

MalaCards based summary : Trichohepatoenteric Syndrome 2, is also known as thes2, and has symptoms including thin, sparse hair An important gene associated with Trichohepatoenteric Syndrome 2 is SKIV2L (Ski2 Like RNA Helicase). The drugs Ferrous gluconate and Iron have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and brain, and related phenotypes are decreased serum iron and hypertelorism

UniProtKB/Swiss-Prot : 76 Trichohepatoenteric syndrome 2: A syndrome characterized by intrauterine growth retardation, severe diarrhea in infancy requiring total parenteral nutrition, facial dysmorphism, immunodeficiency, and hair abnormalities, mostly trichorrhexis nodosa. Hepatic involvement contributes to the poor prognosis of affected patients.

Related Diseases for Trichohepatoenteric Syndrome 2

Diseases in the Trichohepatoenteric Syndrome 1 family:

Trichohepatoenteric Syndrome 2

Symptoms & Phenotypes for Trichohepatoenteric Syndrome 2

Human phenotypes related to Trichohepatoenteric Syndrome 2:

33 (show all 20)
# Description HPO Frequency HPO Source Accession
1 decreased serum iron 33 occasional (7.5%) HP:0040303
2 hypertelorism 33 HP:0000316
3 failure to thrive 33 HP:0001508
4 hepatomegaly 33 HP:0002240
5 prominent forehead 33 HP:0011220
6 immunodeficiency 33 HP:0002721
7 hepatitis 33 HP:0012115
8 intrauterine growth retardation 33 HP:0001511
9 cirrhosis 33 HP:0001394
10 diarrhea 33 HP:0002014
11 wide nose 33 HP:0000445
12 woolly hair 33 HP:0002224
13 sparse hair 33 HP:0008070
14 trichorrhexis nodosa 33 HP:0009886
15 pili canaliculi 33 HP:0002235
16 small for gestational age 33 HP:0001518
17 uncombable hair 33 HP:0030056
18 brittle hair 33 HP:0002299
19 villous atrophy 33 HP:0011473
20 colitis 33 HP:0002583

Symptoms via clinical synopsis from OMIM:

58
Head And Neck Eyes:
hypertelorism

Abdomen Liver:
hepatomegaly
cirrhosis
hepatitis, chronic, nonspecific
iron deposition (in some patients)

Prenatal Manifestations:
intrauterine growth retardation

Abdomen Gastrointestinal:
villous atrophy
colitis
diarrhea, severe and intractable

Growth Height:
decreased height

Immunology:
immune deficiency

Laboratory Abnormalities:
decreased serum iron (in some patients)

Growth Other:
failure to thrive
intrauterine growth retardation (iugr)

Head And Neck Face:
prominent forehead
square forehead
prominent cheeks

Skin Nails Hair Hair:
woolly hair
trichorrhexis nodosa
uncombable hair
brittle hair
thin, sparse hair
more
Growth Weight:
low birth weight

Head And Neck Nose:
flat, broad nose

Cardiovascular Heart:
cardiac abnormalities

Clinical features from OMIM:

614602

UMLS symptoms related to Trichohepatoenteric Syndrome 2:


thin, sparse hair

Drugs & Therapeutics for Trichohepatoenteric Syndrome 2

Drugs for Trichohepatoenteric Syndrome 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1589)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ferrous gluconate Approved Phase 4 299-29-6
2
Iron Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
3
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1 155206-00-1 5311027
4
Insulin glulisine Approved Phase 4,Phase 3 207748-29-6
5
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
6
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
7
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 134523-00-5 60823
8
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
9
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
10
Fenofibrate Approved Phase 4,Phase 2 49562-28-9 3339
11
Pravastatin Approved Phase 4 81093-37-0 54687
12
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 185243-69-0
13
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-56-6 439302 53477758
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 437-38-7 3345
15
Succinylcholine Approved Phase 4 306-40-1 5314
16
Atropine Approved, Vet_approved Phase 4,Phase 3 51-55-8, 5908-99-6 174174
17
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
18
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
19
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 65856 123628
20
Citalopram Approved Phase 4,Phase 2,Not Applicable 59729-33-8 2771
21
Esomeprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
22
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
23
Famotidine Approved Phase 4,Phase 2 76824-35-6 3325
24
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-45-6 774
25
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
26
Cilostazol Approved, Investigational Phase 4,Phase 3 73963-72-1 2754
27
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
28
Aminolevulinic acid Approved Phase 4,Phase 3 106-60-5 137
29
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
30
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
31
Donepezil Approved Phase 4,Phase 2 120014-06-4 3152
32
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
33
Saxagliptin Approved Phase 4,Phase 3,Not Applicable 361442-04-8 11243969
34
Glipizide Approved, Investigational Phase 4,Phase 2 29094-61-9 3478
35 Ethiodized oil Approved, Investigational Phase 4,Not Applicable 8008-53-5
36
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
37
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 38904 10339178 498142
38
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
39
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 159351-69-6 6442177 70789204
40
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
41
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53123-88-9 46835353 6436030 5284616
42
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
43
Propranolol Approved, Investigational Phase 4,Not Applicable,Early Phase 1 525-66-6 4946
44
Pantoprazole Approved Phase 4,Phase 1 102625-70-7 4679
45
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
46
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
47
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
48
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2 142340-99-6 60871
49
Tegafur Approved, Investigational Phase 4,Phase 2 17902-23-7 5386
50
Natalizumab Approved, Investigational Phase 4,Phase 3 189261-10-7

Interventional clinical trials:

(show top 50) (show all 4482)
# Name Status NCT ID Phase Drugs
1 The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
2 The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
3 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
4 Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Unknown status NCT02471105 Phase 4 Preserved Bimatoprost 0.01%;Tafluprost Unit Dose Preservative Free 15microgram/ml
5 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
6 TReatment by Insulin Continuous Infusion in Type 2 DIAbetes Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
7 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
8 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
9 Prevention of Iron Deficiency in 2nd Year of Life Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
10 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
11 Rapid Onset Action of Salbutamol Versus Formoterol Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
12 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
13 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
14 The Effect of Biannual Monitoring With Magnetic Resonance Imaging (MRI), X-ray, or Usual Care on Treatment for Inflammatory Arthritis Unknown status NCT00808496 Phase 4
15 A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack Unknown status NCT01230411 Phase 4 Ibuprofen
16 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
17 Spinal Cord Stimulation (SCS) in Refractory Angina Unknown status NCT00121654 Phase 4
18 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
19 LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients Unknown status NCT02077257 Phase 4 Rosuvastatin
20 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
21 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
22 Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) Unknown status NCT01914367 Phase 4
23 Sufficient Treatment of Peripheral Intervention by Cilostazol Unknown status NCT00912756 Phase 4 cilostazol
24 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
25 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
26 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
27 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
28 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
29 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
30 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
31 Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels Unknown status NCT01374776 Phase 4 Double blind, randomized, placebo controlled inter
32 RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) Unknown status NCT01239953 Phase 4
33 RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) Unknown status NCT01239940 Phase 4
34 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
35 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
36 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER- Unknown status NCT02028234 Phase 4 Pantoprazole,;Omeprazole
37 PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
38 Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors Unknown status NCT00611494 Phase 4 MMF;EC-MPS
39 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
40 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
41 Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
42 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
43 Ventilator Associated Pneumonia in Taper Guard Versus Normal Tube in ICU Patients Unknown status NCT01501227 Phase 4
44 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
45 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
46 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
47 Levobupivacaine Prolonged Wound Infusion for Postoperative Pain Relief After Breast Surgery Unknown status NCT02035904 Phase 4 Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia);saline;Levobupivacaine continuous infusion;morphine;Patrol
48 Amoxicillin Clavulanate in Treatment of Acute Otitis Media Unknown status NCT00299455 Phase 4 amoxicillin-clavulanate;Placebo
49 Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal Unknown status NCT00896012 Phase 4 Rapamune (sirolimus/rapamycin);Tacrolimus
50 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4 Montelukast;Placebo

Search NIH Clinical Center for Trichohepatoenteric Syndrome 2

Genetic Tests for Trichohepatoenteric Syndrome 2

Genetic tests related to Trichohepatoenteric Syndrome 2:

# Genetic test Affiliating Genes
1 Trichohepatoenteric Syndrome 2 30 SKIV2L

Anatomical Context for Trichohepatoenteric Syndrome 2

MalaCards organs/tissues related to Trichohepatoenteric Syndrome 2:

42
Prostate, Testes, Brain, Bone, Kidney, Skin, B Cells

Publications for Trichohepatoenteric Syndrome 2

Variations for Trichohepatoenteric Syndrome 2

UniProtKB/Swiss-Prot genetic disease variations for Trichohepatoenteric Syndrome 2:

76
# Symbol AA change Variation ID SNP ID
1 SKIV2L p.Val341Gly VAR_067721 rs281875237

ClinVar genetic disease variations for Trichohepatoenteric Syndrome 2:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SKIV2L NM_006929.5(SKIV2L): c.848G> A (p.Trp283Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 6, 31961605: 31961605
2 SKIV2L NM_006929.5(SKIV2L): c.848G> A (p.Trp283Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 6, 31929382: 31929382
3 SKIV2L NM_006929.4(SKIV2L): c.1022T> G (p.Val341Gly) single nucleotide variant Pathogenic rs281875237 GRCh37 Chromosome 6, 31929789: 31929789
4 SKIV2L NM_006929.4(SKIV2L): c.1022T> G (p.Val341Gly) single nucleotide variant Pathogenic rs281875237 GRCh38 Chromosome 6, 31962012: 31962012
5 SKIV2L NM_006929.5(SKIV2L): c.1635_1636insA (p.Gly546Argfs) insertion Pathogenic GRCh38 Chromosome 6, 31963721: 31963722
6 SKIV2L NM_006929.5(SKIV2L): c.1635_1636insA (p.Gly546Argfs) insertion Pathogenic GRCh37 Chromosome 6, 31931498: 31931499
7 SKIV2L NM_006929.4(SKIV2L): c.2341-2A> G single nucleotide variant Pathogenic GRCh37 Chromosome 6, 31934779: 31934779
8 SKIV2L NM_006929.4(SKIV2L): c.2341-2A> G single nucleotide variant Pathogenic GRCh38 Chromosome 6, 31967002: 31967002

Expression for Trichohepatoenteric Syndrome 2

Search GEO for disease gene expression data for Trichohepatoenteric Syndrome 2.

Pathways for Trichohepatoenteric Syndrome 2

GO Terms for Trichohepatoenteric Syndrome 2

Sources for Trichohepatoenteric Syndrome 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....